https://doi.org/10.4081/cardio.2023.2
SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials
Supplementary Material: 18
HTML: 15
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: The aim of this paper is to assess the impact of sodium-glucose cotransporters-2 (SGLT2) inhibitors on all-cause and cardiovascular (CV) death in high-risk patients and compare the efficacy of empagliflozin and dapagliflozin.
Methods: PubMed was queried from inception to the last week of September 2023 for randomized controlled trials that compared SGLT2 inhibitors’ empagliflozin or dapagliflozin with placebo and included patients with heart failure (HF), type 2 diabetes mellitus (T2DM), or chronic kidney disease (CKD). The outcome of interest was CV death or all-cause death. Hazard ratios (HR) with 95% confidence intervals (CI) were pooled using a random effect model, and forest plots were created to analyze the results visually. A chi-square test was performed to assess subgroup differences between empagliflozin and dapagliflozin.
Results: Eight trials (N=55,818) were included in our analysis, namely EMPA-REG, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY, DECLARE-TIMI, DAPA-HF, DELIVER and DAPA-CKD. Pooled analysis demonstrated that compared to placebo, SGLT2 inhibition reduced the risk of CV death (SGLT2i arm = 1405 events, 29,089 total patients; placebo arm = 1515 events, 26,729 total patients; HR: 0.85; 95%CI: 0.79-0.93, p<0.001) and all-cause death (SGLT2i arm = 2,491 events, 29,062 total patients; placebo arm= 2,625 events, 26,729 total patients; HR: 0.86; 95% CI 0.79-0.95, p=0.002) in high-risk patients identified as having either T2DM, HF, or CKD. No differences were observed in the effect of empagliflozin and dapagliflozin on CV death (HRempagliflozin: 0.81; 95% CI 0.68-0.97, HRdapagliflozin: 0.88; 0.82-0.95, p=0.39) and all-cause death (HRempagliflozin: 0.86; 95% CI 0.73-1.02, HRdapagliflozin: 0.87; 0.78-0.97, p=0.94).
Conclusions: SGLT2 inhibitors reduce the risk of all-cause and CV death in high-risk patients. Notably, there were no discernible differences in the benefits of empagliflozin and dapagliflozin on these outcomes.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Sven Christopher Aland, Christoph Gertler, Hannah Leonie Bräunig, Timo Schröder, Frank Edelmann, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Anja Sandek, Exercise capacity, iron deficiency and depressive symptoms in patients with asymptomatic chronic systolic heart failure , Global Cardiology: Vol. 2 No. 2 (2024)
- Rafael Vidal-Pérez, Ewa A. Jankowska, The scientific targets: the myocardium, the vasculature and the body’s response to heart failure , Global Cardiology: Vol. 2 No. 1 (2024)
- Babalawan Muhammad, Naser A. Ishaq, Kamilu M. Karaye, Clinical profiles and short-term outcomes of women with peripartum and dilated cardiomyopathies , Global Cardiology: Vol. 2 No. 3 (2024)
- Javed Butler, Sanjiv J. Shah, Melissa Magwire, Carlos Campos, Muhammad Shariq Usman, Anthony Hoovler, Anup Sabharwal, Barry A. Borlaug, Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients , Global Cardiology: Vol. 2 No. 2 (2024)
- Ali A. Youssef, Shaima Al-Omani, Mustafa A. Alrefae, Ahmad Suliman, Reem Hassan, Omar Saleh, Zizi S. Khalifa, New left ventricular thrombus and embolic events in left ventricular dysfunction postmyocardial infarction , Global Cardiology: Vol. 2 No. 3 (2024)
- Giuseppe M.C. Rosano, Jerneja Farkas, Evolving targets for heart failure: the journey so far , Global Cardiology: Vol. 1 No. 1 (2023)
- Marwan M. Refaat, Nadim El Jamal, Hebah M. El-Rayess, Anthony Gebran, Amar M. Salam, The impact of diurnal fasting during Ramadan on patients with established cardiac disease: a systematic review , Global Cardiology: Vol. 2 No. 2 (2024)
- Muhammad Shariq Usman, Arsalan Hamid, Shurjeel Uddin Qazi, Mikhail N. Kosiborod, Deepak L. Bhatt, Muhammad Shahzeb Khan, Muthiah Vaduganathan, Javed Butler, The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis , Global Cardiology: Vol. 2 No. 2 (2024)
- Petros Fountoulakis, Aikaterini Siama, Aimilianos Kalogeris, Marianthi Iliopoulou, Athanasios Tsoukas, Athanasios Manolis, Tricuspid valve fungal endocarditis in a patient with breast cancer and an implantable chemotherapy venous access port , Global Cardiology: Vol. 1 No. 1 (2023)
- Kamilu M. Karaye, Idris Y. Mohammed, Okechukwu S. Ogah, Basil N. Okeahialam, Rationale and design for the peripartum cardiomyopathy in Nigeria (PEACE) registry , Global Cardiology: Vol. 1 No. 1 (2023)
You may also start an advanced similarity search for this article.
